SHORT COMMUNICATION
170 Aortoiliac thrombosis related to COVID-19- A case report
Sainz-González, F., Martínez-Izquierdo, A, Abdelkader- Abu-Sneimeh, A.
SUMMARY: We present a case of acute arterial ischemia in left lower limb due to aortoiliac thrombosis in a patient with
SARS-CoV-2 pneumonia with severe respiratory distress. Abdominal CT angiography was performed with high suspect of
left iliofemoral and right femoropopliteal compromise without cardioembolic risk factors nor previous intermittent claudi-cation.
Despite patient’s poor condition, who needed supplementation of high flow oxygen, a salvage surgery was performed
in order to preserve the extremity. The intervention was performed under local anesthesia and reverse Trendelenburg position
in order to keep appropriate oxygen saturation. The procedure consisted of mechanical iliofemoral thromboembolectomy of
the symptomatic limb achieving functional recovery.
KEY WORDS: Ischemia, COVID-19, aortoiliac.
TECHNICAL NOTES
173 Positive assessment of drugs: January, February, March 2020
Granda-Lobato P., Pedraza-Nieto L., Aparicio-Hernández R., García-Luque A.
SUMMARY: The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency
made public in April and June of 2020, and considered of interest to the healthcare professional, are reviewed. These are
positive technical reports prior to the authorization and placing on the market of the product.
KEYWORDS: Bempedoic Acid, Nilemdo®; Bempedoic Acid/ Ezetimibe, Nustendi®; Cefiderocol, Fetcroja®; Crisaborole,
Staquis®; Darolutamide, Nubeqa®; Givosiran, Givlaari®; Indacaterol/mometasone, Atectura Breezhaler®, Bemrist
Breezhaler®; Insulin Lispro, Liumjev®; Isatuximab, Sarclisa®; Onasmnogene Abeparvovec, Zolgensma®; Ozanimod, Zeposia®;
Pretomanid, Pretomanid Fgk®; Semaglutide, Rybelsus®; Treprostinil sodium, Trepulmix®; Influenza Vaccine, Fluad Tetra®;
Cholera Vaccine, Vaxchora®.
177 Positive assessment of drugs: April, May and June 2020
Aparicio-Hernández R. , García-Luque A., Sánchez-de-Castro M., García-Cerezuela M..
SUMMARY: The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency
made public in April, May and June 2020, and considered of interest to the healthcare professional, are reviewed. These are
positive technical reports prior to the authorization and placing on the market of the product.
KEYWORDS: Alpelisib (Piqray®); Bulevirtida (Hepcludex®); Elexacaftor/ Tezacaftor/ Ivacaftor (Kaftrio®); Entrectinib (Ro-zlytrek
®); Glasdegib (Daurismo®); Imlifidasa (Idefirix®); Indacaterol/ Glicopirronio/ Furoato de mometasona(Enerzair Bree-zhaler
® y Zimbus Breezhaler®); Lefamulina (Xenleta®); Luspatercept (Reblozyl®); Remdesivir (Veklury®); Vacuna frente al
Ébola (MVA-BN-Filo multivalente, recombinante, no-replicativo) (Mvabea®); Vacuna frente al Ébola (Vacuna monovalente
recombinante incapaz de replicar con vector ad26 que codifica la longitud completa de glicoproteína (gp) de ebolavirus zaire)
(Zabdeno®).
REPORTS
183 Performance of the General Defense Hospital in Zaragoza during the pandemic caused by the new SARS-CoV-19 coronavirus
Moreno-Moreno M., Rípodas-Navarro A., Ayensa-Vázquez J.A., López-Jurado M.I,, Ferriz-Pérez S.
SUMMARY: The pandemic caused by the SARS-CoV-2 virus has been a true health tragedy worldwide, generating serious
consequences of morbidity and mortality, especially in older people. The General Defense Hospital (HGDZ) has participated
in Operation Balmis of the Armed Forces (FAS) to fight against this pandemic. It has required HGDZ great flexibility and
adaptability to face the high demand for admission of patients infected with this virus. To this aim, it has implemented a
growing set of measures focused on strengthening the response in the health field and reducing contagion rates.
KEYWORDS. Operation Balmis, pandemic, coronavirus, SARS-CoV-2, COVID-19.
186 Military Institute of Preventive Medicine for the Defence (IMPDEF) activity during Balmis Operation
Mayo-Montero E., Salinas-Granell M., Suárez-Prieto A., Colmenar-Jarillo G., Blanco-Arechabaleta R., Martínez-Rituerto
MT, Arribas-Andes C., Cáceres-Bermejo G., Piñeyroa-Sierra A., Aríñez Fernández MC.
SUMMARY: The Military Institute of Preventive Medicine for the Defence (IMPDEF) has played an important role during
Balmis Operation in preventive medicine and public health in the field of the Armed Forces. The aim has been to provide guid-ance
for case surveillance of COVID-19 and the adoption of measures related with force health protection, maintenance of
force operativity and provide information as part of medical education. This article aims to present the role of the IMPDEF
during the Balmis Operation providing recommendations for public health policy and interventions in the units in Spain and
for the deployed forces.
KEYWORDS: COVID-19, prevention, force health protection.
138 Sanid. mil. 2020; 76 (3)